- Home
- MYN vs CDXC Comparison
MYN vs CDXC Comparison
Compare MYN & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- CDXC
- Stock Information
- Founded
- MYN 1992
- CDXC 1999
- Country
- MYN United States
- CDXC United States
- Employees
- MYN N/A
- CDXC N/A
- Industry
- MYN Finance Companies
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- MYN Finance
- CDXC Health Care
- Exchange
- MYN Nasdaq
- CDXC Nasdaq
- Market Cap
- MYN 411.5M
- CDXC 415.5M
- IPO Year
- MYN N/A
- CDXC N/A
- Fundamental
- Price
- MYN $10.24
- CDXC $6.09
- Analyst Decision
- MYN
- CDXC Strong Buy
- Analyst Count
- MYN 0
- CDXC 2
- Target Price
- MYN N/A
- CDXC $8.00
- AVG Volume (30 Days)
- MYN 86.0K
- CDXC 431.2K
- Earning Date
- MYN 01-01-0001
- CDXC 03-05-2025
- Dividend Yield
- MYN 4.12%
- CDXC N/A
- EPS Growth
- MYN N/A
- CDXC N/A
- EPS
- MYN N/A
- CDXC 0.02
- Revenue
- MYN N/A
- CDXC $91,668,000.00
- Revenue This Year
- MYN N/A
- CDXC $18.64
- Revenue Next Year
- MYN N/A
- CDXC $20.72
- P/E Ratio
- MYN N/A
- CDXC $311.55
- Revenue Growth
- MYN N/A
- CDXC 9.95
- 52 Week Low
- MYN $8.47
- CDXC $1.36
- 52 Week High
- MYN $10.62
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- MYN 52.37
- CDXC 57.85
- Support Level
- MYN $10.00
- CDXC $5.17
- Resistance Level
- MYN $10.25
- CDXC $5.52
- Average True Range (ATR)
- MYN 0.09
- CDXC 0.26
- MACD
- MYN 0.03
- CDXC 0.10
- Stochastic Oscillator
- MYN 72.73
- CDXC 86.92
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests primarily in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.